Vikas S. Ostwal, MD, discusses data for trastuzumab emtansine (T-DM1) as second-line therapy in patients with HER2-positive advanced biliary tract cancers.
Vikas S. Ostwal, MD
Advertisement
Articles by Vikas S. Ostwal, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5